Fate Therapeutics, Inc.FATE was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 21% since Oct 22, 2015.
The company has seen 4 positive and 1 negative estimate revisions in the past 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting that more solid trading could be ahead for Fate Therapeutics. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.
Fate Therapeutics currently has a Zacks Rank #2 (Buy).
Another top-ranked biotechnology stock is Achillion Pharmaceuticals, Inc. ACHN , sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACHILLION PHARM (ACHN): Free Stock Analysis Report
FATE THERAPEUTC (FATE): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
